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Abstract The aim of the present work was to analyze
c-fos response within the trigeminal nucleus caudalis
(TNC) of pinealectomized rats and animals that received
intraperitoneal melatonin, after intracisternal infusion of
capsaicin, used to induce intracranial trigeminovascular
stimulation. Experimental groups consisted of animals that
received vehicle solution (saline–ethanol–Tween 80, 8:1:1,
diluted 1:50) only (VEI, n = 5); animals that received
capsaicin solution (200 nM) only (CAP, n = 6); animals
submitted to pinealectomy (PX, n = 5); sham-operated
animals (SH, n = 5); animals submitted to pinealectomy
followed by capsaicin stimulation (200 nM) after 15 days
(PX ? CAP, n = 7); and animals that received capsaicin
solution (200 nM) and intraperitoneal melatonin (10 mg/
kg) (CAP ? MEL, n = 5). Control rats, receiving vehicle
in the cisterna magna, showed a small number of c-fos-
positive cells in the TNC (layer I/II) as well as the sham-
operated and pinealectomized rats, when compared to
animals stimulated by capsaicin. On the other hand, pine-
alectomized rats, which received capsaicin, presented the
highest number of c-fos-positive cells. Animals receiving
capsaicin and melatonin treatment had similar expression
of the vehicle group. Our data provide experimental evi-
dence to support the role of melatonin and pineal gland in
the pathophysiology of neurovascular headaches.
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Introduction
Migraine is a common condition with significant impact in
the general population [1–3]. In spite of its relevancy,
migraine neurobiology has not been fully determined.
Several mechanisms are important, including the trigemi-
novascular concept [4]. Neurovascular network is thought
to be the anatomical substrate for neurovascular headaches
such as migraine and cluster headaches [5, 6]. A-d and
unmyelinated C-fibers of the trigeminal nerve transmit
painful stimuli from meninges to trigeminal nucleus cau-
dalis (TNC) within the brain stem, via the trigeminal
ganglion (TG) neurons [7]. The pathophysiology of neu-
rovascular headaches is unclear but the involvement of
trigeminovascular system is generally accepted [8].
c-fos expression within the TNC is induced experi-
mentally after stimulation at various sites of the
trigeminovascular system, such as meninges, TG and
superior sagittal sinus [9]. Development of animal models
and the use of direct electrical, mechanical or chemical
F. C. Tanuri  E. de Lima  F. R. Cabral 
E. A. Cavalheiro  D. Amado
Departamento de Neurologia/Neurocirurgia, Universidade
Federal de Sa˜o Paulo, Escola Paulista de Medicina,
Sa˜o Paulo, Brazil
F. C. Tanuri  M. F. P. Peres  E. A. Cavalheiro 
E. Zukerman  D. Amado
Hospital Israelita Albert Einstein, Sa˜o Paulo, Brazil
J. Cipolla-Neto
Departamento de Fisiologia e Biofı´sica, Instituto de Cieˆncias
Biome´dicas, Universidade de Sa˜o Paulo, Sa˜o Paulo, Brazil
M. da Grac¸a Naffah-Mazzacoratti
Departamento de Bioquı´mica, Universidade Federal de Sa˜o
Paulo, Escola Paulista de Medicina, Sa˜o Paulo, Brazil
F. C. Tanuri (&)
Rua Guana´s, 77 Jardim Salgado Filho,
Marı´lia (SP) CEP: 17502-560, Brazil
e-mail: ftanuri@yahoo.com.br
123
J Headache Pain (2009) 10:105–110
DOI 10.1007/s10194-009-0097-3
irritants stimulus (capsaicin, carrageenan and blood) have
been used to mimic vascular head pain [10–13].
c-fos protein is a transcription factor expressed by
immediate-early response of c-fos gene and has been
accepted as a marker of functional activity in neurons [14,
15]. c-fos expression in layers I and II of the TNC is used
to study the activity of the sensory part of the trigeminal
system [16, 17]. This expression can be attenuated by
pharmacological agents used for the treatment of migraine,
including sumatriptan, dihydroergotamine and valproate
[18, 19].
Melatonin, a hormone synthesized by the pineal gland
with major influence on several circadian physiological
activities, is maximally produced between midnight and
dawn, with low levels during the light period [20]. Mela-
tonin has been linked to migraine and other headaches,
increasing evidence supports its role in mechanisms and
treatment of headache disorders [21, 22]. Some headaches
have a clear seasonal and circadian pattern, such as cluster
and hypnic headaches. Melatonin levels have been found
decreased in both migraine and cluster headaches [23–25].
Melatonin is related to headache pathophysiology in sev-
eral ways. Due to its anti-inflammatory effect, free radical
scavenging process, reduction of pro-inflammatory cyto-
kine upregulation, nitric oxide synthase activity and
dopamine release inhibition, membrane stabilization,
GABA and opioid analgesia potentiation, protection
against glutamate neurotoxicity, neurovascular regulation,
5-HT modulation and due to its similarity with the chem-
ical structure of indomethacin. However, little is known
about the putative effect of melatonin in experimental
models of headache [26].
Thus, the aim of this study is to characterize the pattern
of cerebral c-fos expression after noxious trigeminal
stimulation in the group that received melatonin and in
pinealectomized rats, using intracisternal administration of
the capsaicin to appraise the pinealectomy and the mela-
tonin effect in head pain.
Methods
Animals
All experimental protocols were approved by the ethical
committee of the Universidade Federal de Sa˜o Paulo
(UNIFESP) and all efforts were made to minimize animal
suffering following the proposal of International Ethical
Guideline for Biomedical Research [27]. Wistar adult male
rats (250–300 g) housed under environmentally controlled
conditions in a 12/12 h light/dark and granted free access
to food and water were used. These animals were separated
into four groups.
Groups
VEI (n = 5): animals that received vehicle solution only;
CAP (n = 6): animals that received capsaicin solution
(200 nM) only; PX (n = 5): animals that were submitted to
pinealectomy; SH (n = 5): animals that were sham-operated;
PX ? CAP (n = 7): animals submitted to pinealectomy fol-
lowed by capsaicin stimulation (200 nM) after 15 days;
and CAP ? MEL (n = 5) animals that received capsaicin
solution (200 nM) and intraperitoneal melatonin (Sigma,
10 mg/kg) 20 min after capsaicin injection.
Drugs
Capsaicin solution was prepared with 3.05 mg capsaicin
(Merck) per 1 ml of vehicle (saline–ethanol–Tween 80,
8:1:1) and diluted 1:50 (200 nM) with saline. Vehicle was
diluted 1:50 in saline.
Surgical procedures
Pinealectomy
Pinealectomy was performed following the method descri-
bed by Siuciak and Dubocovich [28]. In brief, rats were
anesthetized (pentobarbital, 40 mg/kg i.p.) and fixed in a
stereotaxic frame. Using a pointed dental burr, a piece of
bone was removed at the juncture of the lambda and the
sagittal suture lines. The pineal was grasped with fine forceps
and removed. The bone disk was returned to its original
position and the skin flaps pulled together. In sham-operated
rats, all procedures mentioned above were used, except for
the fact that the pineal gland was not removed.
Capsaicin stimulation
For this procedure, all rats were anesthetized with pento-
barbital (40 mg/kg i.p.) and a surgical opening in the
region between the scalp and C1 (first cervical vertebra)
was made. An amount of 10 ll of capsaicin solution (see
‘‘Drugs’’) was injected into the cisterna magna (over
15 min) using a Hamilton syringe with the aid of a ste-
reotaxic frame [29]. To avoid capsaicin outflow, the needle
was only removed 10 min after injection.
Perfusion and immuno-histochemistry
Two hours after infusion, the rats were anesthetized with
pentobarbital overdose (120 mg/kg), followed by perfu-
sion via the ascending aorta with 0.1 M phosphate saline
buffer (PBS, 200 ml, pH 7.4) and 4% paraformaldehyde
(200 ml) in 0.1 M phosphate buffer (PB, pH 7.4). Brain
stem with attached cervical cord was stored overnight in
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the same fixative and then placed in a cryoprotectant
(30% sucrose in 0.1 M PB, pH 7.4). Coronal serial
sections (40 lm) were prepared on a cryostat microtome
at -20C and collected in PBS with sodium azide
(0.1%) to Nissl staining and immuno-histochemistry. c-
fos protein expression was characterized in free-floating
sections according to the following protocol. Sections
were rinsed three times 5 min in PBS, pre-treated with
0.3% H2O2 in PBS for 15 min, rinsed three times 5 min
in PBS and pre-incubated in 10% bovine serum albumin
(Calbiochem) and 2% normal serum (Vector) in PBS for
2 h at room temperature. Sections were incubated for
48 h at 4C in PBS solution containing 2% BSA, 2%
normal serum, anti-c-fos antibody (1:1,000; Calbiochem)
and 0.3% Triton X-100 in PBS. Following three washes
in PBS, the sections were incubated in a PBS solution
contained biotinylated rabbit IgG (1:200) (Vector) for
2 h at room temperature. Sections were rinsed three
times 5 min in PBS and incubated with the avidin–
biotin–peroxidase complex (Vector) in PBS for 1 h and
30 min at room temperature. Sections were rinsed twice
5 min in PBS and 5 min in Tris–HCl (pH 7.6) and
revealed with 0.06% 3,30-diaminobenzidine tetrahydro-
chloride (Sigma) and with 0.002% H2O2. Sections were
then mounted in slides and dehydrated through alcohol
to xylene and coverslipped with Entellan (Merck).
Nissl staining
Brain stem slices (40 lm) were hydrated in alcohol solu-
tions of decreased concentration followed by staining in
0.5% cresyl Violet acetate (Sigma) diluted in 0.1 M acetate
buffer pH 4.0. Slices were dehydrated, coverslipped and
analyzed by light microscopy optic Zeiss Axiolab.
Quantifications
c-fos immunoreactive cells in the TNC layer I/II were
counted at 0 to -1 mm caudal to obex. Three sections per
animal were analyzed. The count of c-fos immunoreactive
cells was performed using magnification of 2009 under a
microscope optical system Zeiss Axiolab. Representative
images of the brain stem slices were digitalized using NIH
Image 1.61 system. Cell counting was performed blinded
by three observers and the results are expressed as the
mean ± standard deviation.
Statistical analysis
Data were analyzed using one-way analyses of variance
(ANOVA) followed by Tukey’s Q test. A value of
P \ 0.05 was accepted as significant.
Results
Nissl-stained coronal sections of brain stem in control rats
showed a preserved cytoarchitecture (Fig. 1a) and the TNC
(layer I/II) was observable in Fig. 1b. Sections of the other
groups showed similar or normal Nissl staining (data not
shown).
The pattern of c-fos expression was different in the
studied groups. Controls rats receiving vehicle in the cis-
terna magna showed a small number of c-fos-positive cells
(VEI: 9.8 ± 2.42; P \ 0.01) in the TNC (layer I/II) as well
as the sham-operated rats (SH: 3.26 ± 0.15; P \ 0.001),
pinealectomized rats (PX: 2.3 ± 0.78; P \ 0.001) and rats
that received capsaicin and melatonin (CAP ? MEL:
10.53 ± 2.78; P \ 0.01), when compared to capsaicin-
treated animals (CAP: 25.7 ± 8.78). On the other hand,
pinealectomized rats that received capsaicin presented the
highest number of c-fos-positive cells (PX ? CAP:
41.5 ± 6.68; P \ 0.01). A diffuse staining in regions that
were not considered in the present work was observed. The
results of c-fos expression in the immuno-histochemistry
and the quantification of these c-fos-positive cells are
observed in Figs. 2 and 3, respectively.
Discussion
Our results show experimental evidence for the putative
role of melatonin and pineal gland in the pathophysiology
of neurovascular headaches. A high number of c-fos
Fig. 1 Photomicrographs of Nissl-stained coronal sections of brain
stem. a Brain stem, 920, scale bar 300 lc. b Trigeminal nucleus
caudalis (TNC), 9200, scale bar 150 lc
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capsaicin-induced immunoreactive cells in TNC I and II
layers in pinealectomized rats was found.
In previous studies, intracisternal capsaicin evoked c-fos
expression over the rostro-caudal extent of the TNC [30,
31]. Capsaicin selectively actives nociceptive fibers and the
principal nociceptive innervation of blood vessels of the
subarachnoid space and dura mater originated in the tri-
geminal ganglion. According to Kemper [32], the number
of c-fos immunoreactive cells in TNC I/II is capsaicin
dose-dependent and indicates a direct and specific rela-
tionship between c-fos expression and the capsaicin
concentration used. In the present work, the trigemino-
vascular system was activated by 200 nM capsaicin. The
ventrolateral, mediolateral and dorsomedial part of the
TNC are innervated by, respectively, the ophthalmic,
maxillary and mandibular branches of the trigeminal nerve.
All three branches carry fibers that innervate the meninges
and meningeal vasculature [33], which were demonstrated
in the present study by the increased c-fos expression in all
dorsoventral parts of the TNC I/II after the intracranial
capsaicin administration. This increase was intensified by
the pinealectomy procedure.
Melatonin reduces lipid peroxidation process, enhances
the antioxidative enzymes activities and scavenges toxic-
free radical. Furthermore, melatonin inhibits the production
of adhesion molecules that promote the sticking of leuko-
cytes to endothelial cells, attenuating transendothelial cell
migration and edema [34]. It inhibits the synthesis of
prostaglandins acting via anti-inflammatory effect and
reduces the upregulation of the pro-inflammatory cyto-
kines, interleukins and TNFa [35]. Melatonin inhibits the
activity of nitric oxide synthase and dopamine release,
potentiates the inhibitory effect of GABA in the central
nervous system, modulates the serotonin receptors and
potentiates the opioid analgesic. Its structure is similar to
indomethacin that inhibits COX activity [36, 37]. Thus,
several mechanisms could be involved in our results.
Experimental studies demonstrated that pinealectomy
increases the damage in focal cerebral ischemia and
facilitates the epileptogenic process in rats, showing that
melatonin has a neuroprotective action [38, 39].
In this study, we have found a great number of c-fos
immunoreactive cells capsaicin induced in TNC I/II layers
in pinealectomized rats, when compared with the control
group, indicating that pineal gland may be potentially
involved in the pathophysiology of neurovascular head-
aches. This finding was not observed when animals
received melatonin intraperitoneally.
Several studies have evidenced low levels of melatonin
in blood of patients with migraine, chronic migraine and
cluster headache chronic [40, 41]. This data suggest an
inadequate release of this hormone, which could be
responsible for decreasing its protective role against pain,
Fig. 2 Photomicrographs of the
Fos expression in the TNC/II
layers. a Tissue from animal
that received vehicle; b tissue
from capsaicin-injected animal;
c tissue from animal that
received capsaicin and
melatonin; d tissue from
pinealectomized animal; e tissue
from sham-operated animal; and
f tissue from pinealectomized
rat that received capsaicin
injection. 9200, scale bar
150 lc. Arrow shows positive-
like staining that was counted as
c-fos-positive cells
Fig. 3 Quantification of the c-fos protein immunoreactive cells in
rats that received: VEI, vehicle (n = 5); SH, sham-operated rats
(n = 5); PX, pinealectomized rats (n = 5); PX ? CAP, pinealectom-
ized rats that received capsaicin injection (n = 7); CAP, rats that
received capsaicin (n = 6); CAP ? MEL, rats that received capsaicin
and melatonin (n = 5) and were killed 120 min after injection. Cells
were counted in 40 lm sections sampled in the TNC layers I and II at
0 to -1 mm caudal to obex (3 sections). *P \ 0.01 compared with
capsaicin-treated animals; **P \ 0.001 compared with vehicle only,
sham-operated and pinealectomized rats
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via several mechanisms described above. The exact
mechanism, however, has yet to be determined in future
studies. It is less likely that other structures or substances
may play a role in these findings, since melatonin is the
main secretory product of the pineal gland and no other
brain structure were affected during pinealectomy.
Melatonin is a potential candidate for migraine treat-
ment [42]. A significant headache response was found in a
study looking the effect of melatonin 3 mg/day for
migraine prevention [43].
Melatonin has also been studied in cluster headache and
other trigemino-autonomic cephalgias with preliminary
good results. Our study is supporting melatonin
supplementation as an effective suppressing agent of
trigeminovascular activation in an experimental model.
Conclusion
Our data provide experimental evidence to support the role
of melatonin and pineal gland in the pathophysiology of
neurovascular headaches.
Conflict of interest None.
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